Roth Capital Maintains Buy on CervoMed, Lowers Price Target to $11

Benzinga Newsdesk www.benzinga.com Negative 54.4%

Neg 54.4% Neu 0% Pos 0%

Roth Capital analyst Boobalan Pachaiyappan maintains CervoMed (NASDAQ:CRVO) with a Buy and lowers the price target from $19 to $11.